CheckMate 9LA trial: commentary and clinical case report of patient with cerebellar metastasis

Abstract

Patients with non-oncogene-addicted metastatic NSCLC are treated with first- line immunotherapy with or without chemotherapy. CheckMate 9LA trial demonstrated survival benefits and safety of dual immunotherapy (nivolumab, ipilimumab) with limited chemotherapy.

Survival outcomes were significantly improved in patients with tumor PD-L1 expression < 1% and baseline brain metastases. We present a clinical case of a 72 years old patient with NSCLC and cerebellar metastasis treated according to CheckMate 9LA trial.

Keywords

• NSCLC
• stage IV
• CheckMate 9LA
• brain metastases
• case report